-
1
-
-
80051829496
-
Development of antiretroviral drug resistance
-
Wainberg MA, Zaharatos GJ, Brenner BG. 2011. Development of antiretroviral drug resistance. N Engl J Med 365:637-646. http://dx.doi.org/10.1056/NEJMra1004180.
-
(2011)
N Engl J Med
, vol.365
, pp. 637-646
-
-
Wainberg, M.A.1
Zaharatos, G.J.2
Brenner, B.G.3
-
2
-
-
84888099693
-
What if HIV were unable to develop resistance against a new therapeutic agent?
-
Wainberg MA, Mesplede T, Raffi F. 2013. What if HIV were unable to develop resistance against a new therapeutic agent? BMC Med 11:249. http://dx.doi.org/10.1186/1741-7015-11-249.
-
(2013)
BMC Med
, vol.11
, pp. 249
-
-
Wainberg, M.A.1
Mesplede, T.2
Raffi, F.3
-
3
-
-
84887052771
-
Dolutegravir plus abacavirlamivudine for the treatment of HIV-1 infection
-
Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutierrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G. 2013. Dolutegravir plus abacavirlamivudine for the treatment of HIV-1 infection. N Engl J Med 369:1807-1818. http://dx.doi.org/10.1056/NEJMoa1215541.
-
(2013)
N Engl J Med
, vol.369
, pp. 1807-1818
-
-
Walmsley, S.L.1
Antela, A.2
Clumeck, N.3
Duiculescu, D.4
Eberhard, A.5
Gutierrez, F.6
Hocqueloux, L.7
Maggiolo, F.8
Sandkovsky, U.9
Granier, C.10
Pappa, K.11
Wynne, B.12
Min, S.13
Nichols, G.14
-
4
-
-
84874411899
-
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 Week results from the randomised, double-blind, non-inferiority SPRING-2 study
-
Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S. 2013. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 381:735-743. http://dx.doi.org/10.1016/S0140-6736(12)61853-4.
-
(2013)
Lancet
, vol.381
, pp. 735-743
-
-
Raffi, F.1
Rachlis, A.2
Stellbrink, H.J.3
Hardy, W.D.4
Torti, C.5
Orkin, C.6
Bloch, M.7
Podzamczer, D.8
Pokrovsky, V.9
Pulido, F.10
Almond, S.11
Margolis, D.12
Brennan, C.13
Min, S.14
-
5
-
-
84885948765
-
Oncedaily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 Week results from a randomised, double-blind, non-inferiority trial
-
Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min S. 2013. Oncedaily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 13:927-935. http://dx.doi.org/10.1016/S1473-3099(13)70257-3.
-
(2013)
Lancet Infect Dis
, vol.13
, pp. 927-935
-
-
Raffi, F.1
Jaeger, H.2
Quiros-Roldan, E.3
Albrecht, H.4
Belonosova, E.5
Gatell, J.M.6
Baril, J.G.7
Domingo, P.8
Brennan, C.9
Almond, S.10
Min, S.11
-
6
-
-
84903303497
-
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 Week results from the randomised open-label phase 3b study
-
Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C, Fujiwara T, Min S, ING114915 Study Team. 2014. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 383:2222-2231. http://dx.doi.org/10.1016/S0140-6736(14)60084-2.
-
(2014)
Lancet
, vol.383
, pp. 2222-2231
-
-
Clotet, B.1
Feinberg, J.2
Van Lunzen, J.3
Khuong-Josses, M.A.4
Antinori, A.5
Dumitru, I.6
Pokrovskiy, V.7
Fehr, J.8
Ortiz, R.9
Saag, M.10
Harris, J.11
Brennan, C.12
Fujiwara, T.13
Min, S.14
-
7
-
-
84931262441
-
Integrase strand transfer inhibitors in HIV therapy
-
Mesplede T, Wainberg M. 2013. Integrase strand transfer inhibitors in HIV therapy. Infect Dis Ther 2:83-93. http://dx.doi.org/10.1007/s40121-013-0020-8.
-
(2013)
Infect Dis Ther
, vol.2
, pp. 83-93
-
-
Mesplede, T.1
Wainberg, M.2
-
8
-
-
84894503546
-
A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 144 results
-
Wohl DA, Cohen C, Gallant JE, Mills A, Sax PE, Dejesus E, Zolopa A, Liu HC, Plummer A, White KL, Cheng AK, Rhee MS, Szwarcberg J, GS-US-236-0102 Study Team. 2014. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr 65:e118-e120. http://dx.doi.org/10.1097/QAI.0000000000000057.
-
(2014)
J Acquir Immune Defic Syndr
, vol.65
, pp. e118-e120
-
-
Wohl, D.A.1
Cohen, C.2
Gallant, J.E.3
Mills, A.4
Sax, P.E.5
Dejesus, E.6
Zolopa, A.7
Liu, H.C.8
Plummer, A.9
White, K.L.10
Cheng, A.K.11
Rhee, M.S.12
Szwarcberg, J.13
-
9
-
-
84155164041
-
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: Randomised, double-blind, phase 3, non-inferiority study
-
Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, Zhong L, Margot N, Cheng AK, Chuck SL. 2012. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 12:27-35. http://dx.doi.org/10.1016/S1473-3099(11)70249-3.
-
(2012)
Lancet Infect Dis
, vol.12
, pp. 27-35
-
-
Molina, J.M.1
Lamarca, A.2
Andrade-Villanueva, J.3
Clotet, B.4
Clumeck, N.5
Liu, Y.P.6
Zhong, L.7
Margot, N.8
Cheng, A.K.9
Chuck, S.L.10
-
10
-
-
84870533547
-
Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial
-
Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Lathouwers E, Lefebvre E, Opsomer M, Van de Casteele T, Tomaka F. 2013. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med 14:49-59. http://dx.doi.org/10.1111/j.1468-1293.2012.01060.x.
-
(2013)
HIV Med
, vol.14
, pp. 49-59
-
-
Orkin, C.1
DeJesus, E.2
Khanlou, H.3
Stoehr, A.4
Supparatpinyo, K.5
Lathouwers, E.6
Lefebvre, E.7
Opsomer, M.8
Van De Casteele, T.9
Tomaka, F.10
-
11
-
-
84863393356
-
Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir
-
Quashie PK, Mesplede T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA. 2012. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 86:2696-2705. http://dx.doi.org/10.1128/JVI.06591-11.
-
(2012)
J Virol
, vol.86
, pp. 2696-2705
-
-
Quashie, P.K.1
Mesplede, T.2
Han, Y.S.3
Oliveira, M.4
Singhroy, D.N.5
Fujiwara, T.6
Underwood, M.R.7
Wainberg, M.A.8
-
12
-
-
84897975407
-
Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors
-
Oliveira M, Mesplede T, Quashie PK, Moisi D, Wainberg MA. 2014. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS 28:813-819. http://dx.doi.org/10.1097/QAD.0000000000000199.
-
(2014)
AIDS
, vol.28
, pp. 813-819
-
-
Oliveira, M.1
Mesplede, T.2
Quashie, P.K.3
Moisi, D.4
Wainberg, M.A.5
-
13
-
-
84882912698
-
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study
-
Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S, Extended SAILING Study Team. 2013. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 382:700-708. http://dx.doi.org/10.1016/S0140-6736(13)61221-0.
-
(2013)
Lancet
, vol.382
, pp. 700-708
-
-
Cahn, P.1
Pozniak, A.L.2
Mingrone, H.3
Shuldyakov, A.4
Brites, C.5
Andrade-Villanueva, J.F.6
Richmond, G.7
Buendia, C.B.8
Fourie, J.9
Ramgopal, M.10
Hagins, D.11
Felizarta, F.12
Madruga, J.13
Reuter, T.14
Newman, T.15
Small, C.B.16
Lombaard, J.17
Grinsztejn, B.18
Dorey, D.19
Underwood, M.20
Griffith, S.21
Min, S.22
more..
-
14
-
-
84907429695
-
Is resistance to dolutegravir possible when this drug is used in first-line therapy?
-
Mesplede T, Wainberg MA. 2014. Is resistance to dolutegravir possible when this drug is used in first-line therapy? Viruses 6:3377-3385. http://dx .doi.org/10.3390/v6093377.
-
(2014)
Viruses
, vol.6
, pp. 3377-3385
-
-
Mesplede, T.1
Wainberg, M.A.2
-
15
-
-
84874039772
-
Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
-
Mesplede T, Quashie PK, Osman N, Han Y, Singhroy DN, Lie Y, Petropoulos CJ, Huang W, Wainberg MA. 2013. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 10:22. http://dx.doi.org/10.1186/1742-4690-10-22.
-
(2013)
Retrovirology
, vol.10
, pp. 22
-
-
Mesplede, T.1
Quashie, P.K.2
Osman, N.3
Han, Y.4
Singhroy, D.N.5
Lie, Y.6
Petropoulos, C.J.7
Huang, W.8
Wainberg, M.A.9
-
16
-
-
84892453291
-
The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness
-
Wares M, Mesplede T, Quashie PK, Osman N, Han Y, Wainberg MA. 2014. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology 11:7. http://dx.doi.org/10.1186/1742-4690-11-7.
-
(2014)
Retrovirology
, vol.11
, pp. 7
-
-
Wares, M.1
Mesplede, T.2
Quashie, P.K.3
Osman, N.4
Han, Y.5
Wainberg, M.A.6
-
17
-
-
84908253044
-
Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity
-
Mesplede T, Osman N, Wares M, Quashie PK, Hassounah S, Anstett K, Han Y, Singhroy DN, Wainberg MA. 2014. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. J Antimicrob Chemother 69:2733-2740. http://dx.doi.org/10.1093/jac/dku199.
-
(2014)
J Antimicrob Chemother
, vol.69
, pp. 2733-2740
-
-
Mesplede, T.1
Osman, N.2
Wares, M.3
Quashie, P.K.4
Hassounah, S.5
Anstett, K.6
Han, Y.7
Singhroy, D.N.8
Wainberg, M.A.9
-
18
-
-
84873633830
-
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study
-
Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, Poizot-Martin I, Richmond G, Soriano V, Ait-Khaled M, Fujiwara T, Huang J, Min S, Vavro C, Yeo J, VIKING Study Group. 2013. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study. J Infect Dis 207:740-748. http://dx.doi.org/10.1093/infdis/jis750.
-
(2013)
J Infect Dis
, vol.207
, pp. 740-748
-
-
Eron, J.J.1
Clotet, B.2
Durant, J.3
Katlama, C.4
Kumar, P.5
Lazzarin, A.6
Poizot-Martin, I.7
Richmond, G.8
Soriano, V.9
Ait-Khaled, M.10
Fujiwara, T.11
Huang, J.12
Min, S.13
Vavro, C.14
Yeo, J.15
-
19
-
-
0029885139
-
Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins
-
Keulen W, Boucher C, Berkhout B. 1996. Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins. Antiviral Res 31:45-57. http://dx.doi.org/10.1016/0166-3542(96)00944-8.
-
(1996)
Antiviral Res
, vol.31
, pp. 45-57
-
-
Keulen, W.1
Boucher, C.2
Berkhout, B.3
-
20
-
-
0029024089
-
Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC)
-
Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C, Kwok S, Sninsky J, Boucher CAB. 1995. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 171:1411-1419. http://dx.doi.org/10.1093/infdis/171.6.1411.
-
(1995)
J Infect Dis
, vol.171
, pp. 1411-1419
-
-
Schuurman, R.1
Nijhuis, M.2
Van Leeuwen, R.3
Schipper, P.4
De Jong, D.5
Collis, P.6
Danner, S.A.7
Mulder, J.8
Loveday, C.9
Christopherson, C.10
Kwok, S.11
Sninsky, J.12
Boucher, C.A.B.13
-
21
-
-
0037118912
-
M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine
-
Ait-Khaled M, Stone C, Amphlett G, Clotet B, Staszewski S, Katlama C, Tisdale M, CNA3002 International Study Team. 2002. M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS 16:1686-1689. http://dx.doi.org/10.1097/00002030-200208160-00017.
-
(2002)
AIDS
, vol.16
, pp. 1686-1689
-
-
Ait-Khaled, M.1
Stone, C.2
Amphlett, G.3
Clotet, B.4
Staszewski, S.5
Katlama, C.6
Tisdale, M.7
-
22
-
-
0034851899
-
Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples
-
Miller MD, Margot NA, Hertogs K, Larder B, Miller V. 2001. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides Nucleotides Nucleic Acids 20:1025-1028. http://dx.doi.org/10.1081/NCN-100002483.
-
(2001)
Nucleosides Nucleotides Nucleic Acids
, vol.20
, pp. 1025-1028
-
-
Miller, M.D.1
Margot, N.A.2
Hertogs, K.3
Larder, B.4
Miller, V.5
-
23
-
-
0034867418
-
Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations
-
Devereux HL, Emery VC, Johnson MA, Loveday C. 2001. Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J Med Virol 65:218-224. http://dx.doi.org/10.1002/jmv.2023.
-
(2001)
J Med Virol
, vol.65
, pp. 218-224
-
-
Devereux, H.L.1
Emery, V.C.2
Johnson, M.A.3
Loveday, C.4
-
24
-
-
66149141029
-
OpenEpi: A web-based epidemiologic and statistical calculator for public health
-
Sullivan KM, Dean A, Soe MM. 2009. OpenEpi: a web-based epidemiologic and statistical calculator for public health. Public Health Rep 124:471-474.
-
(2009)
Public Health Rep
, vol.124
, pp. 471-474
-
-
Sullivan, K.M.1
Dean, A.2
Soe, M.M.3
-
25
-
-
84921962113
-
Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors
-
Hassounah SA, Mesplede T, Quashie PK, Oliveira M, Sandstrom PA, Wainberg MA. 2014. Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors. J Virol 88:9683-9692. http://dx.doi.org/10.1128/JVI.00947-14.
-
(2014)
J Virol
, vol.88
, pp. 9683-9692
-
-
Hassounah, S.A.1
Mesplede, T.2
Quashie, P.K.3
Oliveira, M.4
Sandstrom, P.A.5
Wainberg, M.A.6
-
27
-
-
0022495870
-
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone
-
Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59:284-291.
-
(1986)
J Virol
, vol.59
, pp. 284-291
-
-
Adachi, A.1
Gendelman, H.E.2
Koenig, S.3
Folks, T.4
Willey, R.5
Rabson, A.6
Martin, M.A.7
-
28
-
-
0029063578
-
Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): Failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1
-
Lusso P, Cocchi F, Balotta C, Markham PD, Louie A, Farci P, Pal R, Gallo RC, Reitz MS, Jr. 1995. Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol 69:3712-3720.
-
(1995)
J Virol
, vol.69
, pp. 3712-3720
-
-
Lusso, P.1
Cocchi, F.2
Balotta, C.3
Markham, P.D.4
Louie, A.5
Farci, P.6
Pal, R.7
Gallo, R.C.8
Reitz, M.S.9
-
29
-
-
0017710978
-
Characteristics of a human cell line transformed by DNA from human adenovirus type 5
-
Graham FL, Smiley J, Russell WC, Nairn R. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36:59-74. http://dx.doi.org/10.1099/0022-1317-36-1-59.
-
(1977)
J Gen Virol
, vol.36
, pp. 59-74
-
-
Graham, F.L.1
Smiley, J.2
Russell, W.C.3
Nairn, R.4
-
30
-
-
67749110262
-
Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1
-
Platt EJ, Bilska M, Kozak SL, Kabat D, Montefiori DC. 2009. Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J Virol 83:8289-8292. http://dx.doi.org/10.1128/JVI.00709-09.
-
(2009)
J Virol
, vol.83
, pp. 8289-8292
-
-
Platt, E.J.1
Bilska, M.2
Kozak, S.L.3
Kabat, D.4
Montefiori, D.C.5
-
31
-
-
57349139455
-
Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research
-
Takeuchi Y, McClure MO, Pizzato M. 2008. Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J Virol 82:12585-12588. http://dx.doi.org/10.1128/JVI.01726-08.
-
(2008)
J Virol
, vol.82
, pp. 12585-12588
-
-
Takeuchi, Y.1
McClure, M.O.2
Pizzato, M.3
-
32
-
-
0036090585
-
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
-
Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46:1896-1905. http://dx.doi.org/10.1128/AAC.46.6.1896-905.2002.
-
(2002)
Antimicrob Agents Chemother
, vol.46
, pp. 1896-1905
-
-
Wei, X.1
Decker, J.M.2
Liu, H.3
Zhang, Z.4
Arani, R.B.5
Kilby, J.M.6
Saag, M.S.7
Wu, X.8
Shaw, G.M.9
Kappes, J.C.10
-
33
-
-
0033856458
-
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120
-
Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 74:8358-8367. http://dx.doi.org/10.1128/JVI.74.18.8358-8367.2000.
-
(2000)
J Virol
, vol.74
, pp. 8358-8367
-
-
Derdeyn, C.A.1
Decker, J.M.2
Sfakianos, J.N.3
Wu, X.4
O'Brien, W.A.5
Ratner, L.6
Kappes, J.C.7
Shaw, G.M.8
Hunter, E.9
-
34
-
-
0031954686
-
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1
-
Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72:2855-2864.
-
(1998)
J Virol
, vol.72
, pp. 2855-2864
-
-
Platt, E.J.1
Wehrly, K.2
Kuhmann, S.E.3
Chesebro, B.4
Kabat, D.5
|